NEW YORK--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a leading U.S.-based multi-platform clinical-stage gene therapy ...
Rocket Pharmaceuticals Announces Clearance from the Spanish Agency for Medicines and Health Products for the Phase 2 Registration-enabling FANCOLEN-II Study of RP-L102 for Fanconi Anemia - BioSpace
Read More
Bagikan Berita Ini
0 Response to "Rocket Pharmaceuticals Announces Clearance from the Spanish Agency for Medicines and Health Products for the Phase 2 Registration-enabling FANCOLEN-II Study of RP-L102 for Fanconi Anemia - BioSpace"
Post a Comment